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Abstract 
 
The Controlling Cancer Summit is an intimate informal meeting that annually gathers 
international academic and clinical researchers to network and debate the current 
advancements and challenges of oncology research. This year it focused not only on 
diagnostic/prognostic biomarkers and genetic influences in cancer, but also novel and 
sometimes unconventional therapeutic interventions. This report will summarise the 
meeting highlights that contribute to our comprehension of cancer biology and new 
innovative ways to target this disease. 
 
DNA damage and repair  
 
TP53 is activated by DNA damage, and consequently initiates a cascade of events 
leading to DNA repair or programmed cell death. It is therefore crucial for 
suppressing tumourigenesis, and several talks at the summit were dedicated to p53 
function.  
Dr. Leandro Castellano from Imperial College London presented findings describing 
the role of p53 in miRNA processing and function. Using isogenic HCT116 (TP53+/+ 
and TP53-/-) cell lines, the group identified that variable direct association of p53 with 
AGO2 (a catalytic component of the RNA-induced silencing complex) regulates its 
interaction with miRNA during DNA damage response, triggered by doxorubicin. 
Various oncogenic mutant forms of TP53 decreased miRNA binding to AGO2, 
compared to wild-type TP531, suggesting that p53 regulates miRNA-mediated post-
transcriptional gene repression in cancer.  
Platinum agents, such as cisplatin or dicycloplatin, are widely used in cancer therapy 
and also trigger DNA damage repair pathway. Dr. Jing Jie Yu of Mary Babb 
Randolph Cancer Centre demonstrated a direct relationship between p53 activation in 
response to platinum therapy and checkpoint kinase 2 (Chk2) phosphorylation. Using 
transient overexpression of TP53 in ovarian cancer cell lines, the author showed 
doubling of Chk2 phosphorylation. Similarly, siRNA-mediated knockdown of p53 
significantly reduced Chk2 phosphorylation. Importantly, inhibition of Chk2 with a 
small molecule inhibitor enhanced efficacy of cisplatin in vitro, suggesting a role for 
such compounds in targeting resistance to platinum agents.  
Temozolomide is another DNA-damaging agent, widely used in treatment of brain 
cancer, but prone to swift development of resistance. Prof. Anthony Berdis of 
Cleveland State University shared his findings on tackling this issue using metal-
containing nucleosides. Following analysis of several nucleoside analogues, one 
analogue demonstrated consistent insertion opposite cytidine and thymine; and a 
corresponding nucleoside revealed potent anti-proliferative effects in haemotological 
and adherent cancer cell lines. These findings were validated in vivo using solid 
cancer subcutaneous xenografts2. Given the unique ability of this analogue to be 
incorporated in the lesions created by temozolomide, misreplication was inhibited, 
thereby enhancing temozolomide’s therapeutic window. 
 
Exosomes: broad applications in cancer 
 
In our stride for personalised medicine, as a cancer research community, we have 
explored the power of biomarkers for targeted treatment, genetic testing and more 
recently, “liquid biopsies” to investigate the potential of circulating tumour DNA and 
exosomes in cancer. Exosomes are small membrane vesicles (30-100nm) hosting 
specific proteins and lipids, mRNA and miRNA, and can be released by any cell 
type3. Given numerous functional properties of exosomes, such as molecule transport 
and cell-cell communication, they received a lot of attention in cancer research as 
stimulators of immune response and vehicles for drug delivery. Both of these areas 
were discussed at the summit. 
Prof. Susanne Gabrielsson from Karolinka Institute described the role of exosomes 
derived from dendritic cells (dexosomes) in stimulating the immune system. 
Dexosomes are capable of stimulating several types of immune response, and together 
with molecule-carrying ability, they comprise an appealing putative cancer treatment. 
Using various T and B cell knockout mouse models, Prof. Gabriellson’s group 
showed that dexosomes loaded with MHC class I and II peptides were not sufficient 
to elicit CD4+ or CD8+ T cell responses and that immune stimulation depended on 
functional B cells4. In vivo CD8+ T cell activation was superior when dexosomes 
were loaded with a whole-molecule antigen, rather than a peptide, as dexosomes 
containing whole ovalbumin (OVA) protein offered better protection against OVA-
overexpressing tumour. This tumour-specific response was amplified upon co-loading 
of exosomes with alpha-galactosylceramide, a glycolipid that induces a rapid 
activation of invariant natural killer T cells5. Interestingly, Prof. Gabrielsson’s work 
challenges the central role of MHC class I in exosome stimulation of T cell response. 
In a B16/OVA mouse melanoma model, allogeneic and syngeneic exosomes 
stimulated similar percentages of T cells infiltrating the tumour. The author 
hypothesised that dendritic cells most likely take up both types of exosomes, 
consequently inducing antigen-specific T and B cell response, thereby bypassing the 
requirement for patient’s own exosomes6. 
Another function of exosomes discussed at the summit was its potential to deliver 
anti-cancer compounds. Brain cancers are among the deadliest cancers and are 
particularly hard to reach with a systemic therapy due to blood-brain barrier. Yet 
neural stem cells, such as human mesenchymal stromal stem cells (MSC), have been 
shown to infiltrate glioma cells in the brain. Prof. Chaya Brodie of Bar-Ilan 
University demonstrated the use of these stem cells in therapy against brain tumours. 
Expression of select miRNAs demonstrated therapeutic potential in many in vitro 
models, but this approach still lacks effective delivery in vivo. Specifically, miR-124 
and miR-145 overexpression in glioma (stem) cells was reported to significantly 
decrease cell migration and self-renewal in vitro, respectively7. The author suggested 
that miR-124 regulates cell migration via lamininγ1 and intergrin β1, whereas 
differentiation was altered by its effect on CDK6. Inhibitory effects of miR-145 were 
attributed to its repression of Sox2 and Oct4. In glioma xenografts, successful 
delivery of these fluorescently labelled miRNAs (and also pre-miRNA) enclosed in 
exosomes was demonstrated to be gap junction-dependent and cell contact-
independent8. Altogether, these findings have a major implication in therapeutic 
miRNA delivery to the brain in cancer and also in neurodegenerative disorders.  
 
Natural nanomedicines as cancer therapeutics 
 
Of course, in addition to miRNA and siRNA, natural (and synthetic) molecules may 
also be entrapped in lipid vesicles. There were several natural anti-cancer compounds 
discussed at the summit and are summarised below.  
Dr. Christine Dufès of University of Strathclyde spoke about the therapeutic potential 
of a green tea extract, epigallocatechin-3-gallate (EGCG). The author firstly 
demonstrated that 3-diaminobutyric polypropylenimine dendrimer (DAB) conjugation 
to transferrin resulted in highly selective tumour targeting. Intravenous administration 
of this dendriplex complexed with TNFa-encoding DNA resulted in sustained tumour 
regression in vivo, using A431 epidermoid carcinoma xenograft model, with 90% 
complete response and 10% partial regression over a course of one month of 
treatment9. Consequently, the authors encapsulated the natural EGCG in these 
transferrin-bearing vesicles and used it for treatment of A431 (epidermoid) and B16-
F10 (melanoma) xenografts. Tumour suppression reached 40% in both models, with 
improved overall survival, compared to the control mice10, thereby highlighting a role 
for this green tea extract as an anti-cancer therapy.  
Anti-tumour activities of cardiac glycosides have been known for decades, yet their 
molecular mechanism of tumour suppression remained unclear. One such type of 
cardiac glycosides, named UNBS1450, is extracted from the plant Calotropis 
procera, and Prof. Marc Diederich described its anticancer properties at the summit. 
The group focused on the effects exerted by UNBS1450 on Bcl-2 anti-apoptotic 
proteins. Using adherent and non-adherent cell lines of various cancer types they 
identified MCL-1 as a key mediator of anti-proliferative properties of UNBS1450. 
MCL-1 downregulation occurred at the protein level, via proteasomal degradation, 
and was an essential early step in cell death response mediated by UNBS145011. 
Furthermore, UNBS1450 triggered accumulation of mitochondria in phagophores, 
consequently triggering apoptosis in N-type SH-SY5Y cells12. These studies provided 
a detailed mechanism of anti-proliferative action of select cardiac glycosides.  
However perhaps the most controversial and widely debated natural anti-cancer 
compounds are cannabinoids. Over 60 phytocannabinoids have been identified, yet to 
date there have been only a few attempts at identifying specific cannabinoids 
harbouring therapeutic potential against cancer and their mechanism of action. Dr. 
David Meiri of Technion-Israel Institute of Technology presented some early findings 
using different cannabinoids as anti-proliferative agents in colorectal cancer cell line 
models. His group identified several cannabis extracts with potent anti-proliferative 
properties, exerted through G-coupled receptors, CB1 and CB2. Interestingly, Dr. 
Meiri showed that the delivery method (ingest/inhale) dramatically altered effects of 
individual cannabinoids in a cancer-dependent manner.  
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